Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

Sponsor
MaineHealth (Other)
Overall Status
Completed
CT.gov ID
NCT00792454
Collaborator
(none)
116
1
2
85
1.4

Study Details

Study Description

Brief Summary

The mortality rate of treated patients with end stage renal disease(ESRD)is 22 deaths patient-years at risk in 2006. Incident patients with ESRD are most vulnerable within the first 90 days of dialysis, with an annualized mortality rate of 50 deaths/100 patient years. The vast majority of these deaths are due to cardiovascular causes. As cardiac rehabilitation programs have shown a 20% reduction in one year overall mortality rate post myocardial infarction the investigator proposes that a similar type of rehabilitation program will also have a benificial effect on morbidity and mortality in patients with chronic kidney disease(CKD)and ESRD.The overall goal of this project is to study whether a renal rehabilitation program based on guided exercise implemented in patients with stage III and stage IV CKD can influence the mortality rate of these patients prior to and during the first 90 days of dialysis

Hypothesis:The application of a guided exercise program (renal rehabilitation) instituted in patients with stage III or Stage IV CKD will decrease the mortality rate prior to the initiation of renal replacement therapy.

Hypothesis:The application of renal rehabilitation during the late stages of CKD will decrease the mortality risk during the first 90 days of renal rehabilitation therapy.

Hypothesis:A guided exercise program will have an immediate and prolonged effect on activity levels, mental health and adaption to chronic illness in patients with advanced CKD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: exercise training
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
116 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Study Start Date :
Oct 1, 2008
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: exercise training/renal rehabilitation

Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.

Behavioral: exercise training
Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises. Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet. Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet.

No Intervention: control

Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.

Outcome Measures

Primary Outcome Measures

  1. Mortality prior to and During the First 90 Days of Dialysis [5 years]

Secondary Outcome Measures

  1. Measurement of physical fitness and quality of life [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • greater than 18 yo

  • stage III CKD (GFR<60ml/min)

  • stage IV CKD (GFR<30ml/min)

Exclusion Criteria:
  • active angina pectoris

  • lower extremity amputation with no prosthesis

  • orthopedic disorder severly exacerbated by activity

  • chronic lung disease resulting in significant shortness of breath or oxygen de-saturation at rest

  • cerebro cascular disease manifested by ongoing TIAs

  • malignant carcinoma

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maine Nephrology Associates Portland Maine United States 04102

Sponsors and Collaborators

  • MaineHealth

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
James C Wasserman, principal investigator, MaineHealth
ClinicalTrials.gov Identifier:
NCT00792454
Other Study ID Numbers:
  • 3399
First Posted:
Nov 18, 2008
Last Update Posted:
May 30, 2017
Last Verified:
May 1, 2017
Keywords provided by James C Wasserman, principal investigator, MaineHealth
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2017